Author Index Vol. 52,1995
Camillo Porta(University of Pavia), E. Bajetta, Lorenzo Gianni, Massimo Piergiuseppe Franchi(University of Verona), G. Sgarbossa, Franco Monti(Azienda Unità Sanitaria Locale Rimini), Franco Rovelli, F. Gaion, Ann‐Lii Cheng(National Taiwan University), Giovanna Cavazzini(University of Padua), C.Y. Lee, Hwei‐Fang Tien(Far Eastern Memorial Hospital), P. Nelli, Cristina Noberasco(European Institute of Oncology), Giuseppe Nastasi, Mauro Moroni(University of Milan), Kwok‐Pui Fung(Chinese University of Hong Kong), P. Manente, Anna Tusei, Pier Paolo Fattori(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonio Ardizzoia(Alessandro Manzoni Hospital), Marco Colleoni(European Institute of Oncology), Maria Enrica Forghieri(Azienda Ospedaliera Carlo Poma), Sandro Barni, Heidi Lyng(Oslo University Hospital), Elisabetta Scorbati, Kun‐Huei Yeh(National Taiwan University Hospital), Steven Soon-Kai Kong, Marina Cazzaniga, Franco Frigerio, Flavia Zanaboni, Lurdes A. Marques, Lois M. Mulligan(Queen's University), Nicoletta Donadello, Einar K. Rofstad, Arnaldo Correia de Medeiros, Alberto Ravaioli(Florence (Netherlands)), Fernando Brivio, María Aparecida Nagai(Universidade de São Paulo), Giuseppina Arcangeli, F. Desiderio(Azienda Ospedaliera Carlo Poma), Maria Mitzi Brentani(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Gabriele Tancini, Enrico Aitini, Young-Do Choy, C.P. Lui, Mario Nicolini(Azienda Ospedaliera Carlo Poma), E. Pasquini(Ospedale Infermi di Rimini), Paolo Lissoni, Sylvie Mazoyer(Université Claude Bernard Lyon 1)
Cited by 0
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k